证券代码：600479 证券简称：千金药业 公告编号：2026-003 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 特此公告。 2026年1月20日，国家药品监督管理局网站发布了《中药保护品种公告（第34号）》（2026年第11 号），国家药品监督管理局批准株洲千金药业股份有限公司（以下简称"公司"）的补血益母丸为首家中 药二级保护品种，具体内容如下： ■ 补血益母丸为国基药品种、医保甲类品种、独家品种，被《国家基本药物临床应用指南（中成药）2018 年版》、《中成药临床应用指南（第二版 妇科疾病分册）》、《中医妇科学（全国中医药高等教育十 四五规划教材）》等指南及教科书收录推荐。该产品适用于气血两虚兼血瘀证产后腹痛。 本次公司补血益母丸获批为首家中药二级保护品种，加强了公司产品的知识产权保护，将有利于提升公 司产品在产后恢复用药领域的市场竞争力，对公司的生产经营产生积极的影响。 株洲千金药业股份有限公司 上述事项不会对公司当期经营业绩产生重大影响，药品的销售情况可能受到国家政策、市场环境变化等 因素影响，具有较大不确定性 ...

Core Viewpoint - Qizheng Tibetan Medicine has announced that its subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has received approval for its Ten Flavor Gentian Flower Capsule as the first secondary protected traditional Chinese medicine, with a protection period of seven years from the announcement date [1] Group 1: Product Approval and Market Impact - The Ten Flavor Gentian Flower Capsule is indicated for clearing heat, resolving phlegm, stopping cough, and relieving asthma, primarily used in the treatment of respiratory diseases [1] - This approval is expected to enhance the company's market competitiveness in the respiratory field [1] - The approval will also promote the upgrading of Tibetan medicine quality standards and optimization of product quality [1] Group 2: Market and Regulatory Considerations - The production and sales of the drug are subject to various factors, including market environment changes and industry policies, which introduce a degree of uncertainty [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Chengdu Huasheng Technology Group Co., Ltd.'s Sanqi Tongshu Capsules as the first secondary protected traditional Chinese medicine variety, with a protection period of seven years starting from the announcement date [1][2]. Product Information - Product Name: Sanqi Tongshu Capsules - Dosage Form: Capsule - Specification: 0.2g per capsule - Indications: The product is indicated for promoting blood circulation, alleviating blood stasis, improving cerebral infarction and ischemic dysfunction, restoring ischemic brain metabolism abnormalities, preventing platelet aggregation, and improving microcirculation, primarily used for cerebrovascular embolic diseases such as stroke and hemiplegia [1][3]. Product Overview - Sanqi Tongshu Capsules are derived from the active components of the Sanqi herb, specifically the saponins, and are recognized as a new generation of Sanqi preparations. The product has multiple effects, including preventing thrombosis and promoting nerve function recovery, and has been included in various clinical guidelines for the treatment of cerebrovascular diseases. The product has received several awards for its technological advancements and its active ingredient has been recognized in international pharmacopoeias [3]. Impact on the Company - The approval of Sanqi Tongshu Capsules as a secondary protected variety enhances market protection and is expected to improve the product's core competitiveness, positively impacting the company's operations. However, the short-term impact on the company's financial performance is expected to be limited due to uncertainties in the pharmaceutical industry and market environment [4].